The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 16)
-
AC Immune SA (NASDAQ: ACIU) ( announced clinical trial update for its Alzheimer's vaccine candidate)
-
argenx SE – ADR (NASDAQ: ARGX)
-
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
-
Castle Biosciences Inc (NASDAQ: CSTL)
-
Dynavax Technologies Corporation (NASDAQ: DVAX)(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant)
-
Heat Biologics Inc (NASDAQ: HTBX)
-
Novavax, Inc. (NASDAQ: NVAX)
-
Qiagen NV (NYSE: QGEN)( Thermo Fisher Scientific Inc. (NYSE: TMO) announced a sweetened offer to buy the company)
-
Quest Diagnostics Inc (NYSE: DGX)
-
Otonomy Inc (NASDAQ: OTIC)
-
Principia Biopharma Inc (NASDAQ: PRNB)(reacted to buyout rumors)
-
Relay Therapeutics Inc (NASDAQ: RLAY) (jumped 75.25% on its debut)
-
Sanofi SA (NASDAQ: SNY) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia)
-
TIZIANA LF SCIE/S ADR (NASDAQ: TLSA)
-
West Pharmaceutical Services Inc. (NYSE: WST)
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows July 16)
-
Avidity Biosciences Inc (NASDAQ: RNA)
-
Legend Biotech Corp (NASDAQ: LEGN)
-
Nkarta Inc (NASDAQ: NKTX) (IPOed last Friday)
-
Repare Therapeutics Inc (NASDAQ: RPTX)
-
Tricida Inc (NASDAQ: TCDA) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic acidosis treatment candidate)
Stocks In FocusPhaseBio Doses First Patient In Potentially Pivotal Trial of PB1046 For COVID-19
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has dosed the first patient in a potentially pivotal Phase 2 clinical trial, dubbed VANGARD, to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome, or ARDS.
PB1046 is a novel, once-weekly, subcutaneously-injected VIP receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems, having anti-inflammatory, antifibrotic and potent bronchodilatory and immunomodulatory effects in the respiratory system.
The stock advanced 10.21% to $5.18 in after-hours trading.
Applied DNA Reports Positive Preclinical Data For DNA Vaccine Candidates
Applied DNA Sciences Inc (NASDAQ: APDN) announced linear-DNA forms of COVID-19 vaccine candidates under development by partner Takis Biotech and manufactured by it yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.